

FARMACOSMO: SUPPLEMENT TO THE NOTICE OF CALL OF THE ORDINARY SHAREHOLDERS' MEETING

Naples, April 26th 2023

Farmacosmo S.p.A. ("Company". "Farmacosmo"), a company active in the Health, Pharma & Beauty sector, listed on the Euronext Growth Milan market of Borsa Italiana, announces that the Board of Directors, which met on April 25th 2023, resolved to approve the request to supplement the agenda items submitted on April 23rd 2023 by the shareholder DECO F S.r.l. ("**DECO F**"), providing for the inclusion of the following additional item:

"3) Nomination of a member of the Board of Directors; resolutions related and consequent thereto".

The Shareholders' Meeting, convened by a notice published on April 18th 2023 on the Company's website (at www.farmacosmoinvestors.com, in the "Investors/Shareholders' Meetings" section) and by excerpt in the daily newspaper "ItaliaOggi" for May 3rd 2023, at 8:00 a.m., in first and single call, at the Company's registered office in Naples, Via Francesco Crispi No. 51 is therefore convened to discuss and resolve on the following

Agenda

- 1) Consideration and approval of the financial statements for the year ended December 31st 2022; Directors' report on operations for the year 2022; report of the Board of Statutory Auditors and the Independent Auditors; resolutions related and consequent thereto;
- 2) Allocation of net income for the year; resolutions related and consequent thereto;
- 3) Nomination of a member of the board of directors; resolutions related and consequent thereto.

Lastly, it should be noted that, along with the submission of the above-mentioned request to supplement the items on the agenda, DECO F member proposed lawyer Doroty de Rubeis to be appointed as a new director of the Company.

The illustrative report prepared by the shareholder DECO F, pursuant to Article 16 of the Articles of Association of the Company, together with the curriculum vitae of lawyer Doroty de Rubeis and the relevant statement regarding the possession of the requirements prescribed by the applicable legal regulations, are made available to the public at the registered office and on the website of Borsa Italiana, as well as on the Company's website www.farmacosmoinvestors.com, in the section "Investors/Shareholders' Meetings".

Please note that the Company has decided to avail itself of the option provided for in Article 106, paragraph 4, of Decree Law No. 18 of March 17,th 2020 (as last extended), providing - also as an exception to the Articles of Association - that intervention of shareholders at the Shareholders' Meeting takes place exclusively through the designated representative (the "**Designated Representative**"), identified by the Company in Monte Titoli S.p.A, pursuant to Article 135-undecies of Legislative Decree No. 58 of February 24th 1998 ("**TUF**"), without physical attendance at the meeting by shareholders. Pursuant to Article 106, paragraph 4, of the Decree Law "Cura Italia", the Designated Representative may also be granted proxies and/or sub-proxies pursuant to Article 135-novies of the TUF, notwithstanding the provisions of Article 135-undecies, paragraph 4, of the TUF.

Information regarding the persons entitled to attend and exercise voting rights at the Shareholders' Meeting (record date April 21st 2023), right to ask questions before the meeting, right to supplement the list of items on the agenda of the Shareholders' Meeting, the exercise of voting by proxy exclusively through the Designated Representative, the availability of the full text of the proposed resolutions together with the explanatory reports and documents that will be submitted to the Shareholders' Meeting, and the organizational aspects of the Shareholders'

FARMACOSMO+

PRESS RELEASE

Meeting, are set forth in the supplement to the full Notice of Shareholders' Meeting, the text of which is published on the Company's website (at www.farmacosmoinvestors.com, in the "Investors/Shareholders' Meetings" section), to which reference should be made, together with the documents relating to the Shareholders' Meeting, made available within the terms and in the manner prescribed by current regulations.

The extract of the supplement to the notice of meeting was published in the newspapers "Il Sole 24 Ore" and "Milano Finanza" today.

This press release is available on the www.farmacosmoinvestors.com website, section "Investors/Press Releases" and on the authorized storage mechanism "eMarket Storage" (www.emarketstorage.com).

THE SOCIETY

Farmacosmo is a company active in the Health, Pharma & Beauty sectors. The company's business model is based on the circular model of the I(ea)n strategy, and is divided into three main business areas: Logistics, Intelligence and Node. Logistics: enables the management and fulfillment of up to 12,000 orders per day, with delivery times of up to 20 hours from carrier picking and just-in time procurement ('zero warehouse' policy). Intelligence: includes strategy definition, competitive positioning and customer journey activities, which enabled the company to intercept c. 188,000 customers in 2021. Recurring customers contributed 74% of the annual retail stream turnover. The average cart value of active customers in the retail stream amounted to €92 (€109 related to recurring customers). Node: R&D activities, process innovation and IT infrastructure of the company. Over the past five years, Farmacosmo's sales value has grown by 54% (CAGR 2016-2021) and will be around €58 million in 2021. The Farmacosmo ecosystem aims to pursue standards of excellence in every part of its value chain, being inspired by compliance with ESG principles at all stages of the logistics process (from the packaging used for online orders to carbon compensation initiatives) and in the valorisation of its employees, the company's strategic asset. The portals ProfumeriaWeb, Phàrmasi, Bau Cosmesi and ContactU, an innovative platform of telepsychology launched in March 2023, are part of Farmacosmo Group. During 2022, Farmacosmo launched its rooting strategy through the acquisition of Farmacosmo-branded logistics pharmacies. Farmacosmo's commitment to ESG is also underlined by the publication of its Sustainability Report 2021.

IDENTIFICATION CODES

Ordinary Share: ISIN IT0005487670 (Ticker COSMO)

Warrant Farmacosmo 2022-2025: ISIN IT0005487415 (Ticker WCOSMO)

FOR FURTHER INFORMATIONS:

INVESTOR RELATIONS MANAGER

Farmacosmo

Via Crispi, 51 - 80121 Napoli

Tel. +39 02 50042143

Paolo Cimmino ir@farmacosmo.it

EURONEXT GROWTH ADVISOR

Illimity Bank

Via Soperga, 9 - 20124 Milano

Tel. +39 02 82849699

farmacosmo@illimity.com

INVESTOR & MEDIA RELATIONS ADVISOR

IR Top Consulting

Via Bigli, 19 - 20121 Milano

Tel. +39 02 45473883

Pietro Autelitano ir@irtop.com

Domenico Gentile ufficiostampa@irtop.com